Nathan Rout-Pitt

Dr. Nathan Rout-Pitt

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2018 in Respiratory Research
Verified
Journal Article
Open access
PDF file
NRNathan Rout-Pitt
Nathan Rout-Pitt
NFNigel Farrow
Nigel Farrow
DPDavid Parsons
David Parsons
MDMartin Donnelley
Martin Donnelley
Cystic Fibrosis (CF) is a genetic disorder that arises due to mutations in the Cystic Fibrosis Transmembrane Conductance Regulator gene, which encodes for a protein responsible for ion transport out of epithelial cells. This leads to a disruption in transepithelial Cl-, Na + and HCO3− ion transport and the subsequent dehydration of the airway epithelium, resulting in infection, inflammation and development of fibrotic tissue. Unlike in CF, fibrosis in other lung diseases including asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis has been well characterised. One of the driving forces behind fibrosis is Epithelial Mesenchymal Transition (EMT), a process where epithelial cells lose epithelial proteins including E-Cadherin, which is responsible for tight junctions. The cell moves to a more mesenchymal phenotype as it gains mesenchymal markers such as N-Cadherin (providing the cells with migration potential), Vimentin and Fibronectin (proteins excreted to help form the extracellular matrix), and the fibroblast proliferation transcription factors Snail, Slug and Twist. This review paper explores the EMT process in a range of lung diseases, details the common links that these have to cystic fibrosis, and explores how understanding EMT in cystic fibrosis may open up novel methods of treating patients with cystic fibrosis.

1 May 2020 in The American Journal of Pathology
Verified
Journal Article
Closed access
AMAlexandra McCarron
Alexandra McCarron
PCPatricia Cmielewski
Patricia Cmielewski
NRNicole Reyne
Nicole Reyne
CMChantelle McIntyre
Chantelle McIntyre
JFJohn Finnie
John Finnie
MDMartin Donnelley
Martin Donnelley

10 April 2018 in Journal of Biological Methods
Verified
Journal Article
Open access
PDF file
NRNathan Rout-Pitt
Nathan Rout-Pitt
AMAlexandra McCarron
Alexandra McCarron
CMChantelle McIntyre
Chantelle McIntyre
DPDavid Parsons
David Parsons
MDMartin Donnelley
Martin Donnelley
Lentiviral-mediated gene therapy has been proposed for the treatment of a range of diseases, and due to its genome integration properties, it offers the potential for long-lasting benefit from a once-off treatment. Production methods for pre-clinical studies in animal models, and ultimately for human clinical trials, must be capable of producing large quantities of high-quality lentiviral vector in an efficient and cost-effective manner. We report here a medium-scale method (from 1.5 L to 6 L of vector supernatant) for lentiviral vector production in adherent cell cultures using the NUNCâ„¢ EasyFillâ„¢ Cell Factoryâ„¢ from Thermo Fisher Scientific. Downstream purification uses a Mustang Q XT5 anion exchange capsule from Pall, and an ultracentrifugation step to concentrate the vector. This method is capable of producing lentiviral vector with concentrated titres of 108–109 TU/ml, with reduced manual handling compared to single monolayer flask methods.

13 June 2018 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
NFNigel Farrow
Nigel Farrow
WCWCHN Cmielewski
WCHN Cmielewski
MDMartin Donnelley
Martin Donnelley
NRNathan Rout-Pitt
Nathan Rout-Pitt
YMYuben Moodley
Yuben Moodley
DPDavid Parsons
David Parsons
Airway disease is a primary cause of morbidity and early mortality for patients with cystic fibrosis (CF). Cell transplantation therapy has proven successful for treating immune disorders and may have the potential to correct the airway disease phenotype associated with CF. Since in vivo cell delivery into unconditioned mouse airways leads to inefficient engraftment, we hypothesised that disrupting the epithelial cell layer using the agent polidocanol (PDOC) would facilitate effective transplantation of cultured stem cells in mouse nasal airways. In this study, 4 μL of 2% PDOC in phosphate-buffered saline was administered to the nasal airway of mice to disrupt the epithelium. At 2 or 24 h after PDOC treatment, two types of reporter gene-expressing cells were transplanted into the animals: luciferase-transduced human airway basal cells (hABC-Luc) or luciferase-transduced human amnion epithelial cells (hAEC-Luc). Bioluminescence imaging was used to assess the presence of transplanted luciferase-expressing cells over time. Data were evaluated by using two-way analysis of variance with Sidak’s multiple comparison. Successful transplantation was observed when hABCs were delivered 2 h after PDOC but was absent when transplantation was performed 24 h after PDOC, suggesting that a greater competitive advantage for the donor cells is present at the earlier time point. The lack of transplantation of hAECs 24 h after PDOC supports the importance of choosing the correct timing and cell type to facilitate transplantation. These studies into factors that may enable successful airway transplantation of human stem cells showed that extended functioning cell presence is feasible and further supports the development of methods that alter normal epithelial layer integrity. With improvements in efficacy, manipulating the airway epithelium to make it permissive towards cell transplantation may provide another option for safe and effective correction of CF transmembrane conductance regulator function in CF airways.

1 October 2018 in Human Gene Therapy Methods
Verified
Journal Article
Closed access
CMChantelle McIntyre
Chantelle McIntyre
MDMartin Donnelley
Martin Donnelley
NRNathan Rout-Pitt
Nathan Rout-Pitt
DPDavid Parsons
David Parsons
For respiratory research utilising gene vector delivery to the lung, the size of rodent models has typically necessitated relatively “blind” dosing via the nose, via an endotracheal tube, or through a surgical incision into the trachea. This commonly results in a limited ability to reliably dose specific small regions of lung, and contributes to high levels of transduction variability between animals. The resultant poor reliability, reproducibility, and high variability compromises statistical capability, and so demands greater animal sample sizes than should be feasible. We have designed and successfully implemented the first reliable targeted gene vector dosing of small regions in rat lungs using a miniature rigid bronchoscope containing a working channel. Using our setup, this technique can currently access airway branches down to at least the fourth generation in the lungs of rats greater than 200 grams body weight, allowing dosing and redosing of specific lobes via airway branch points in the lung tree. Here we report the protocol for performing this minimally invasive technique, and the effect of delivering vesicular stromatitis virus G (VSV-G) pseudotyped lentivirus to selected lung lobes. Examples of other applications, such as delivery of agar beads, are also shown. We expect that the availability of this technique will substantially enhance gene vector studies in rat models for a range of lung diseases.

1 June 2018 in Human Gene Therapy
Verified
Journal Article
Closed access
NFNigel Farrow
Nigel Farrow
MDMartin Donnelley
Martin Donnelley
PCPatricia Cmielewski
Patricia Cmielewski
EREugene Roscioli
Eugene Roscioli
NRNathan Rout-Pitt
Nathan Rout-Pitt
DPDavid W. Parsons
David W. Parsons
Cystic fibrosis (CF) lung disease is an ideal candidate for a genetic therapy. It has been shown previously that preconditioning with lysophosphatidylcholine (LPC) prior to lentiviral (LV) vector delivery results in long-term in vivo gene expression in the airway epithelium of CF mice. It was hypothesized that this outcome is largely due to transduction of airway basal cells that in turn pass the transgene onto their progeny. The aim of these studies was to confirm if the in vivo delivery of a human immunodeficiency virus type 1 (HIV-1) vesicular stomatitis virus envelope glycoprotein (VSV-G) pseudotyped LV vector following LPC airway conditioning results in transduction of mouse airway basal cells in situ and if the transgene is passed onto their progeny. Additionally, the study sought to determine the efficiency of in vitro transduction of human airway basal cells. First, normal mouse nasal airways were pretreated with LPC prior to delivery of a HIV-1 VSV-G pseudotyped LV vector carrying a LacZ marker gene (LV-LacZ). An epithelial ablation model utilizing polidocanol was then used to demonstrate that clonal outgrowth of linear and spotted clusters of transgene expressing ciliated, basal, and goblet cells occurs following transduction of basal cells. Second, human basal cells were cultured from primary bronchial epithelial cells, with identity confirmed by keratin 5 staining. High levels of transgene expression were found following LV-LacZ transduction. This study demonstrates the ability of the vector delivery protocol to transduce mouse airway basal cells, the LV vector to transduce human basal cells, and the likely role of these cells in maintaining long-term gene expression. These findings support and further develop the potential of LV gene transfer for persistent correction of CF airway disease.